pbm reforms for employee health plans

Summary#

This bill would change rules for how Federal employee health benefit plans deal with pharmacy benefit managers (PBMs). It sets minimum payments that PBMs must make to in‑network pharmacies, limits practices that steer patients to certain pharmacies, and creates penalties and possible debarment for PBMs that break the rules. The broad goal is to raise pharmacy payments, increase transparency at the point of sale, and limit PBM practices seen as harmful to independent or non‑affiliate pharmacies.

• Minimum pharmacy reimbursement: PBMs must pay in‑network pharmacies the ingredient cost equal to the national average drug acquisition cost (NADAC) on the day of adjudication (or wholesale acquisition cost if the drug is not on NADAC), plus the lesser of 4% of that amount or $50.
• Dispensing fee: PBMs must pay a professional dispensing fee equal to the State Medicaid (Title XIX) dispensing fee where the pharmacy is located.
• Rebates at point of sale: PBMs must apply manufacturer rebates at the pharmacy checkout to lower a beneficiary’s coinsurance or copay, and must send the remaining rebate money to the plan carrier (minus the amount the patient saved).
• Prohibitions on PBM practices: PBMs and their affiliates may not steer patients to a specific pharmacy, promote one in‑network pharmacy over another, exclude in‑network pharmacies via network rules, induce manufacturers to limit drug distribution to certain pharmacies, or charge pharmacies back for dispensing fees.
• Ban on retroactive reductions: PBMs may not reduce a pharmacy’s reimbursement by lowering or adjusting claims at or after adjudication.
• Enforcement and penalties: The Office of Personnel Management (OPM) may impose civil penalties ($10,000 per violation), limited caps on total penalties, require remediation plans by carriers, and debar PBMs after a pattern of penalties. The rules take effect one year after enactment.

What it means for you#

• Federal employees, retirees, and dependents (beneficiaries):

  • Your copay or coinsurance could be reduced at the pharmacy if rebates are applied at the point of sale.
  • You should still be free to choose any in‑network pharmacy; the bill bars PBMs from forcing use of a particular pharmacy.

• In‑network pharmacies (including independent and community pharmacies):

  • Pharmacies must be paid ingredient cost based on NADAC (or WAC) plus a small percentage or $50 cap.
  • Pharmacies must receive a professional dispensing fee equal to the State Medicaid dispensing fee where they operate.
  • Pharmacies would be protected from retroactive claim adjustments and many forms of network exclusion or steering by PBMs.

• Pharmacy benefit managers (PBMs) and their affiliates:

  • PBMs must change how they set reimbursements, apply rebates, and run networks.
  • They face new prohibitions on steering and on charging pharmacies fees after adjudication.
  • Violations can trigger civil penalties, remediation requirements for carriers, and eventual debarment from Federal plans.

• Carriers that offer Federal employee health plans:

  • Carriers must ensure their PBMs comply with these rules.
  • If a carrier receives multiple penalties tied to a PBM, the carrier must submit a remediation plan and cooperate with OPM inspections.
  • Carriers must help OPM inspect documents, personnel, and facilities when OPM deems it necessary.

• Drug manufacturers:

  • PBMs are restricted from influencing manufacturers to limit distribution to certain pharmacies. Manufacturers’ existing rebate arrangements would be affected by the requirement to apply rebates at point of sale, though the bill mainly regulates PBMs and carriers.

• Timing:

  • The new rules start one year after the bill becomes law.

Expenses#

No publicly available information.

• The bill text does not include a fiscal note or cost estimate.
• Possible fiscal impacts that follow from the text (not provided in the bill) could include higher prescription costs for the Federal employee health plans, changes to plan administrative costs, and OPM enforcement costs. These are not quantified in the bill text.
• Carriers and PBMs may face compliance costs to change payment systems, contracts, and point‑of‑sale processes. The bill itself does not give dollar estimates.

Proponents' View#

The bill text suggests these goals and reasons supporters may give:

• The bill appears intended to ensure pharmacies get reimbursed at rates tied to actual acquisition cost (NADAC or WAC) plus a set percentage, which could help pharmacies cover drug costs.
• Applying rebates at the point of sale could lower out‑of‑pocket costs for beneficiaries immediately rather than after the fact.
• Banning steering, marketing, and exclusionary network practices could protect patient choice and help independent or non‑affiliate pharmacies compete.
• The civil penalties, remediation plans, and potential debarment give OPM tools to enforce compliance in Federal employee plans.

Opponents' View#

The bill text also raises several possible concerns and trade‑offs:

• One concern is that higher pharmacy reimbursements and mandatory dispensing fees could raise total drug spending for Federal plans. That could lead to higher premiums, employer/employee contributions, or other cost shifts. The bill does not address how the increased payments would be funded.
• The bill does not provide a fiscal estimate. It is unclear how much OPM enforcement and inspections would cost and who would pay those costs.
• It is unclear how the NADAC or WAC rules will work for specialty drugs, clinic or mail‑order settings, or drugs without clear NADAC entries. The bill allows WAC only if NADAC is not available; practical application may be complex.
• The State Medicaid dispensing fee may vary widely by state and may not reflect the cost structure of all pharmacies or dispensing situations (for example, long‑term care, specialty, or home infusion).
• The civil penalty limits and the debarment trigger rely on a multi‑penalty counting system over 10 years. It is unclear how this will work in practice and whether the caps are large enough to deter repeat bad actors.
• The requirement that rebates reduce patient cost at point of sale and that remaining rebates go to carriers could change PBM/manufacturer contracting and might create disputes over how rebates are tracked and remitted.
• The bill does not detail how it interacts with other federal or state laws governing PBMs, Medicaid, Medicare, or private plans.